Impact van de 18F-DCFPyL PET/CT-scan op het behandeladvies voor patiënten met prostaatkanker en een biochemisch recidief na curatieve therapie

Translated title of the contribution: Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study

Dennie Meijer, Rosemarijn H. Ettema, Pim J. van Leeuwen, Pepijn M. J. Oosterholt, Yves J. L. Bodar, Henk G. van der Poel, N. Harry Hendrikse, Maarten L. Donswijk, Maurits Wondergem, Annelies E. Vellekoop, R. Jeroen A. van Moorselaar, Jakko A. Nieuwenhuijzen, Daniela E. Oprea-Lager, André N. Vis

Research output: Contribution to journalArticleProfessional

Abstract

The aim of this study was to investigate whether 18F‑DCFPyL PET/CT imaging resulted in a change of decision on treatment management in patients with biochemically recurrent (BCR) prostate cancer. 253 patients with BCR prostate cancer who underwent restaging 18F‑DCFPyL PET/CT were assessed. Two urologists formulated a preferred treatment for each patient before and after knowing the results of the 18F‑DCFPyL PET/CT. In 103/253 cases (40.7%), a preferred treatment change based on the 18F‑DCFPyL PET/CT findings was reported. A positive 18F‑DCFPyL PET/CT (p < 0.001), and positive pathological lymph node status (pN1; p = 0.024) were significant predictors for an intended change of management, whereas a positive surgical margin (p = 0.022) was inversely associated with an intended change of management. It was concluded that, in this study, we found a significant impact of 18F‑DCFPyL PET/CT on the intended management of patients with BCR prostate cancer.
Translated title of the contributionManagement impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study
Original languageDutch
Pages (from-to)89-100
Number of pages12
JournalTijdschrift voor urologie
Volume11
Issue number5
Early online date2021
DOIs
Publication statusPublished - 1 Aug 2021

Keywords

  • F‑DCFPyL PET/CT
  • PSMA
  • biochemical recurrence
  • change of management
  • prostate cancer

Cite this